Cinolazepam
From Drugwiki
Cinolazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada. Cinolazepam is used for management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
| |
| |
Cinolazepam
| |
| Systematic (IUPAC) name | |
| 3-[9-chloro- 6-(2-fluorophenyl)- 4-hydroxy- 3-oxo- 2,5-diazabicyclo [5.4.0]undeca- 5,8,10,12- tetraen- 2-yl] propanenitrile | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H13ClFN3O2 |
| Mol. mass | 357.8 |
| Pharmacokinetic data | |
| Bioavailability | 90-100% |
| Metabolism | Hepatic |
| Half life | 9 h[1] |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Unscheduled(US) |
| Routes | Oral |
Mechanism of action
Cinolazepam binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
Brand names for Cinolazepam
- Gerodorm
Half life of Cinolazepam
9 Hours